Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced it will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 26, 2025, before U.S. markets open. The company's management will host a live webcast at 8 a.m. Eastern Time to discuss financial and operating results.
Participants can access the webcast through the Investor Relations section of Madrigal's website and are advised to register 15 minutes before the scheduled start. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (Nasdaq: MDGL) ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 mercoledì 26 febbraio 2025, prima dell'apertura dei mercati statunitensi. La direzione dell'azienda ospiterà un webcast in diretta alle 8:00 ora orientale per discutere i risultati finanziari e operativi.
I partecipanti possono accedere al webcast attraverso la sezione Relazioni con gli Investitori del sito web di Madrigal e si consiglia di registrarsi 15 minuti prima dell'inizio programmato. Una registrazione sarà disponibile circa due ore dopo l'evento dal vivo.
Madrigal Pharmaceuticals (Nasdaq: MDGL) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el miércoles 26 de febrero de 2025, antes de la apertura de los mercados en EE. UU. La dirección de la empresa llevará a cabo un webcast en vivo a las 8 a.m. hora del Este para discutir los resultados financieros y operativos.
Los participantes pueden acceder al webcast a través de la sección de Relaciones con Inversores del sitio web de Madrigal y se les aconseja registrarse 15 minutos antes del inicio programado. Una repetición estará disponible aproximadamente dos horas después del evento en vivo.
마드리갈 제약(Madrigal Pharmaceuticals, Nasdaq: MDGL)은 2024년 4분기 및 연간 재무 결과를 2025년 2월 26일 수요일, 미국 시장 개장 전에 발표할 것이라고 발표했습니다. 회사 경영진은 동부 표준시 오전 8시에 재무 및 운영 결과에 대해 논의하는 라이브 웹캐스트를 진행할 예정입니다.
참가자는 마드리갈 웹사이트의 투자자 관계 섹션을 통해 웹캐스트에 접근할 수 있으며, 예정된 시작 15분 전에 등록할 것을 권장합니다. 라이브 이벤트 후 약 두 시간 후에 재생이 가능합니다.
Madrigal Pharmaceuticals (Nasdaq: MDGL) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le mercredi 26 février 2025, avant l'ouverture des marchés américains. La direction de l'entreprise animera un webinaire en direct à 8 h, heure de l'Est, pour discuter des résultats financiers et opérationnels.
Les participants peuvent accéder au webinaire via la section Relations avec les investisseurs du site Web de Madrigal et sont invités à s'inscrire 15 minutes avant le début prévu. Un enregistrement sera disponible environ deux heures après l'événement en direct.
Madrigal Pharmaceuticals (Nasdaq: MDGL) hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Mittwoch, den 26. Februar 2025, vor der Eröffnung der US-Märkte veröffentlichen wird. Das Management des Unternehmens wird um 8 Uhr Eastern Time eine Live-Webcast veranstalten, um die finanziellen und operativen Ergebnisse zu erörtern.
Teilnehmer können auf den Webcast über den Bereich Investor Relations der Madrigal-Website zugreifen und wird geraten, sich 15 Minuten vor dem geplanten Beginn zu registrieren. Eine Wiederholung wird etwa zwei Stunden nach der Live-Veranstaltung verfügbar sein.
- None.
- None.
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register here at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Madrigal Pharmaceuticals (MDGL) release Q4 and full-year 2024 earnings?
What time is Madrigal Pharmaceuticals' (MDGL) Q4 2024 earnings call?
How can investors access Madrigal Pharmaceuticals' (MDGL) Q4 2024 earnings webcast?
Will there be a replay available for Madrigal's (MDGL) Q4 2024 earnings webcast?
